Results 121 to 130 of about 15,820 (232)

Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review. [PDF]

World J Diabetes, 2020
Zhang L, Xue S, Hou J, Chen G, Xu ZG.
europepmc   +1 more source

Successful Revascularization of Chronic Total Occlusions in Patients With Chronic Thromboembolic Pulmonary Disease

Catheterization and Cardiovascular Interventions, Volume 107, Issue 7, Page 2323-2334, June 1, 2026.
ABSTRACT Background Chronic thromboembolic pulmonary disease (CTEPD) leads to chronic total occlusions (CTOs) of the pulmonary arteries in a minority of patients. Treatment of CTOs with balloon pulmonary angioplasty (BPA) may substantially improve patient hemodynamics but presents unique technical challenges and has previously been associated with a ...
Elliot J. Stein, Peter J. Leary, Lauren N. Carlozzi, Samuel G. Rayner, Zachary L. Steinberg   +4 more
wiley   +1 more source

Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review. [PDF]

Adv Ther
Habib NG, Adhia A, Lopez D, Sandros M, Guichard P.   +4 more
europepmc   +1 more source

Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe? [PDF]

J Heart Lung Transplant, 2020
Badagliacca R, Sciomer S, Petrosillo N.
europepmc   +1 more source

Survival Improvement With Steroid Use for Pulmonary Veno‐Occlusive Disease With the Aid of Pulmonary Vasodilators and Tyrosine‐Kinase Inhibitor, a Retrospective Study

Clinical Cardiology, Volume 49, Issue 6, June 2026.
This study aimed to assess the efficacy of steroid treatment with pulmonary vasodilators and tyrosine kinase inhibitors in patients with Pulmonary VenoOcclusive Disease (PVOD). Kaplan‐Meier curve showed that survival of PVOD patients with PSL (PRS) was significantly better with Log rank test (p = 0.01) than without PSL (PNS).
Mayumi Finger, Kaori Takeuchi, Hanako Kikuchi, Ayumi Goda, Takumi Inami, Yuichi Tamura, Masaharu Kataoka, Toru Satoh   +7 more
wiley   +1 more source

Synergistic Cardiopulmonary Protection of Endothelin Receptor Antagonists Combined With Soluble Guanylate Cyclase Agonists in High-Risk Coronary Syndrome With Pulmonary Hypertension. [PDF]

Rev Cardiovasc Med
Zhao L, Pang X.
europepmc   +1 more source

Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions

Cancer, Volume 132, Issue S1, 1 June 2026.
Abstract Antibody–drug conjugates (ADCs) represent a major advance in precision oncology, combining the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By enabling targeted intracellular delivery of highly potent payloads, ADCs aim to maximize antitumor activity while minimizing systemic toxicity. This review summarizes
André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo   +3 more
wiley   +1 more source

Endothelin Receptor Antagonists [PDF]

Cardiovascular Drug Reviews, 1994
openaire   +1 more source

Pharmacokinetics and Neuroprotective Efficacy of Poly‐Arginine Peptide R18D in Sprague Dawley Rats Subjected to Transient Intraluminal Filament Middle Cerebral Artery Occlusion Stroke

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
The R18D peptide exhibits a favorable pharmacokinetic profile and significantly reduces infarct volume in a rat model of middle cerebral artery occlusion (MCAO) followed by reperfusion. These findings highlight the potential clinical utility of R18D as a neuroprotective therapy for stroke patients undergoing endovascular recanalization interventions ...
Bruno P. Meloni, Stuart K. Gribble, Meghan G. Thomas, Ayelet Weksler, Lena Finkelstein, Lena Fishtein, Dimitry Kovalchuk, Gilad Maximov, Avital Schauder, Keren Kigel‐Zur, Sigal Meilin   +10 more
wiley   +1 more source

Endothelin Receptor Antagonists for the Treatment of Hypertension: Recent Data from Clinical Trials and Implementation Approach. [PDF]

Curr Cardiol Rep
Manickavasagar R, Krishnan A, Azzam O, Schlaich MP.   +3 more
europepmc   +1 more source